Later in 2017, in a cohort C study [108], Planchard et al. investigated the abovementioned combination therapy (trametinib plus dabrafenib) in patients with treatment-naïve BRAF V600E-mutant metastatic NSCLC. This evidence concerns the gene BRAF and non-small cell lung carcinoma.